Clincosm LogoSign in Get a demo

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT04380714
Collaborator
(none)
700
Enrollment
1
Location
3
Actual Duration (Months)
231.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020.

On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention.

Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence.

However,prisoners have a higher prevalence of substance use disorders than the general population.

What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison.

  • Anonymous questionnaire from the start

  • Collection of socio-demographic data

  • Collection of consumption data before and during containment

  • Collection of monitoring data

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    700 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Cross-Sectional
    Official Title:
    Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.
    Actual Study Start Date :
    May 1, 2020
    Actual Primary Completion Date :
    May 30, 2020
    Actual Study Completion Date :
    Aug 1, 2020

    Outcome Measures

    Primary Outcome Measures

    1. percentage changes in the consumption of psychoactive substances [1 day]

      percentage changes in the consumption of psychoactive substances

    Secondary Outcome Measures

    1. Assessment of the level of stress [1 day]

      Assessment of the level of stress by self-administered questionnaire before / during confinement

    2. Assessment of depression [1 day]

      Assessment of depression by self-administered questionnaire before / during confinement

    3. Craving modification evaluation [1 day]

      Craving modification evaluation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion criteria:

    • Men incarcerated at Villeneuve Les Maguelone prison

    • On a given date (May 12)

    • Major

    • French speaking

    • non illiterate

    Exclusion criteria:

    • minors

    • patients refusing

    • non-French speaking

    • illiterate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UH Montpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Principal Investigator: Aurélie Mieuset, PhD, University Hospitals of Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT04380714
    Other Study ID Numbers:
    • RECHMPL20_0273
    First Posted:
    May 8, 2020
    Last Update Posted:
    Dec 29, 2020
    Last Verified:
    Dec 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Dec 29, 2020